Meeting
2015 ASCO Annual Meeting
A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.
Authors
Kim Allyson Margolin
Stanford University Medical Center and the Cytokine Working Group (CWG), Stanford, CA
Kim Allyson Margolin , Hussein Abdul-Hassan Tawbi , Marc S. Ernstoff , F. Stephen Hodi , David F. McDermott , Robin Edwards , Alexandre Avila , Michael B. Atkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02320058
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS9080)
DOI
10.1200/jco.2015.33.15_suppl.tps9080
Abstract #
TPS9080
Poster Bd #
322b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
First Author: Dirk Schadendorf
Poster
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
First Author: F. Stephen Hodi
Poster
2023 ASCO Annual Meeting
Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).
First Author: Suzanne Phillips